… treatment of mild to moderate COVID-19 infection, there has been a lack of data on the efficacy
among unvaccinated adult … administration of MOV to non-hospitalized patients with mild-to…

… , Molnupiravir and convalescent plasma in non-hospitalized … should be initiated for all
non-hospitalized adults with mild to … In selecting the best pharmacologic treatment available, …

… were treated at the outpatient clinic, of whom 420 were treated with SOT, 398 with N/R and
1788 with MOL. 10 patients (3.2%) who were treated … of non-hospitalized patients (adults and …

… Molnupiravir,” “COVID-19,” and “efficacy.” This meta-analysis included studies that
compared the effectiveness of molnupiravir with a placebo for COVID-19 treatment… of non-hospitalized …

… initially established as a treatment for hospitalized patients with … and death among non-hospitalized
patients with COVID-19 who … to severe disease, including adults of advanced age, …

… Modelbased dose selection for the phase 3 evaluation of molnupiravir (MOV) in the treatment
of COVID-19 in adults. In: Proceedings and abstracts of the 31st Annual Meeting of the …

… Efficacy and safety of molnupiravir for the treatment of non‐hospitalized adults with mild
Covid‐19: a randomized, open‐label, parallel group phase trial 3 trial. Lancet. 2022. …

… For non-hospitalized patients with mild to moderate COVID-19, treatment options include …
A randomized, double-blind, placebo-controlled trial involved non-hospitalized adult patients …

… Finally, we found that about 2% of patients treated with nirmatrelvir/ritonavir and
molnupiravir experienced a … of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386:509–20. …

… the safety and efficacy of molnupiravir in non-hospitalized adults with COVID-19 [15]. The
TriNetX database includes anonymized records for adult patients treated for COVID-19 at …